POLITICO @politico
The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has opened the door for patient advocacy groups to pressure Medicare and private insurers to cover expensive tests needed to concretely diagnose the disease https://t.co/YXlWF2sZHI — PolitiTweet.org